FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1927-1935 May 4, 2006 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.

A 40-year-old obese black woman has had weakness and epigastric pain for several weeks and diarrhea and vomiting for four days. She does not appear acutely ill; physical examination is normal except for abdominal tenderness. Her hematocrit is 25 percent. Her white-cell count and differential count are normal. The platelet count is 10,000 per cubic millimeter. The peripheral-blood smear shows occasional fragmented . . . [Full Text of this Article]

The Clinical Problem

Strategies and Evidence

Evaluation

Management

            Plasma-Exchange Treatment

            Immunosuppressive Agents

            Remission and the Risk of Relapse

Areas of Uncertainty

Guidelines

Conclusions and Recommendations

Source Information

From the Hematology–Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City.

Address reprint requests to Dr. George at the University of Oklahoma Health Sciences Center, Hematology–Oncology Section, Rm. CHB 358, P.O. Box 26901, Oklahoma City, OK 73190, or at james-george@ouhsc.edu.

Related Letters:

Thrombotic Thrombocytopenic Purpura
Matzdorff A. C., George J. N.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:630, Aug 10, 2006. Correspondence

This article has been cited by other articles:

• Burrus, T. M., Wijdicks, E. F.M., Rabinstein, A. A. (2009). Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura. Neurology 73: 66-70 [Abstract] [Full Text]  
• Letchumanan, P., Ng, H.-J., Lee, L.-H., Thumboo, J. (2009). A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology (Oxford) 48: 399-403 [Abstract] [Full Text]  
• De Serres, S. A., Isenring, P. (2009). Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria. Nephrol Dial Transplant 24: 1048-1050 [Abstract] [Full Text]  
• Thomas, M. P., Wang, A. (2008). Taken Out of Context. NEJM 359: 2478-2482 [Full Text]  
• Bedi, N (2008). Thrombotic thrombocytopenic purpura: a true haematological emergency. Emerg. Med. J. 25: 701-702 [Abstract] [Full Text]  
• Sadler, J. E. (2008). Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 112: 11-18 [Abstract] [Full Text]  
• Levey, S. A., Bajwa, R. S., Picken, M. M., Clark, J. I., Barton, K., Leehey, D. J. (2008). Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation. NDT Plus 1: 154-156 [Full Text]  
• Lammle, B., Kremer Hovinga, J. A., George, J. N. (2008). Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. haematol 93: 172-177 [Full Text]  
• Kapiteijn, E., Brand, A., Kroep, J., Gelderblom, H. (2007). Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 18: 1745-1747 [Full Text]  
• Swisher, K. K., Doan, J. T., Vesely, S. K., Kwaan, H. C., Kim, B., Lammle, B., Kremer Hovinga, J. A., George, J. N. (2007). Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. haematol 92: 936-943 [Abstract] [Full Text]  
• Ferrari, S., Scheiflinger, F., Rieger, M., Mudde, G., Wolf, M., Coppo, P., Girma, J.-P., Azoulay, E., Brun-Buisson, C., Fakhouri, F., Mira, J.-P., Oksenhendler, E., Poullin, P., Rondeau, E., Schleinitz, N., Schlemmer, B., Teboul, J.-L., Vanhille, P., Vernant, J.-P., Meyer, D., Veyradier, A., for the French and Clinical Biological Network on, (2007). Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Blood 109: 2815-2822 [Abstract] [Full Text]  
• George, J. N. (2007). Evaluation and Management of Patients With Thrombotic Thrombocytopenic Purpura. J Intensive Care Med 22: 82-91 [Abstract]  
• Francis, K. K., Kalyanam, N., Terrell, D. R., Vesely, S. K., George, J. N. (2007). Disseminated Malignancy Misdiagnosed as Thrombotic Thrombocytopenic Purpura: A Report of 10 Patients and a Systematic Review of Published Cases. The Oncologist 12: 11-19 [Abstract] [Full Text]  
• Matzdorff, A. C., George, J. N. (2006). Thrombotic Thrombocytopenic Purpura. NEJM 355: 630-630 [Full Text]  
• Bratton, S. L. (2006). Fatality in Hemolytic Uremic Syndrome. AAP Grand Rounds 16: 80-80 [Full Text]  
• Sadler, J. E. (2006). Thrombotic Thrombocytopenic Purpura: A Moving Target. ASH Education Book 2006: 415-420 [Abstract] [Full Text]